Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus DEXASPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus DEXASPORIN.
BREO ELLIPTA vs DEXASPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid/Antibiotic Combination